Clinical trial
Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)
NCT00394589 · Merck Sharp & Dohme LLC, Industry · Terminated
Key facts
| NCT number | NCT00394589 |
|---|---|
| Title | Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3) |
| Official title | Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice. |
| Acronym | Re³ |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | Integrated Therapeutics Group Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Infliximab Increased Frequency, Infliximab Increased Dose, Infliximab Control |
| Enrollment | 43 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Nov 1, 2006 |
| Last update posted | Apr 11, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: